ADARx Pharmaceuticals Reports Q3 Results with Narrowing Losses and Increased Collaboration Revenue
ADARx Pharmaceuticals (ADRX) reported its third-quarter financial results, showing a narrowing of GAAP earnings per share losses to -$1.74, compared to -$1.85 in the same period last year. This represents a 6% year-over-year improvement in loss reduction. The company also highlighted significant growth in its collaboration revenue, which rose 43% year-over-year to reach $2.2 million. These results follow recent strategic developments, including discussions regarding an IPO and strong collaboration deals with major pharmaceutical entities like AbbVie.
